Status:
COMPLETED
APT™ T3X on the COVID-19 Contamination Rate
Lead Sponsor:
University of Nove de Julho
Collaborating Sponsors:
Santa Casa de Porto Alegre
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19 must be done on d...
Detailed Description
To achieve the proposed objective it will be performed a randomized, triple blind, placebo-controlled trial. The volunteers will be randomly allocated to two intervention groups: APT™ T3X or placebo. ...
Eligibility Criteria
Inclusion
- good general health (without serious health problems);
- tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain real-time polymerase chain reaction (RT-PCR), for COVID-19.
Exclusion
- previous immunization against COVID-19;
- allergy to tetracycline hydrochloride;
- diagnosis of Lyme disease;
- immunocompromised;
- share housing with someone diagnosed with COVID-19 at the time of the baseline evaluation;
- serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and metabolic diseases, etc.
Key Trial Info
Start Date :
January 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04716426
Start Date
January 28 2021
End Date
March 25 2021
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-074